4.6 Article

ProBDNF as an Indicator of Improvement among Women with Depressive Episodes

Related references

Note: Only part of the references are listed.
Article Psychiatry

Analysis of blood mature BDNF and proBDNF in mood disorders with specific ELISA assays

Liying Lin et al.

Summary: Previous studies showed that blood BDNF levels in mood disorders were reduced. However, little is known about the changes of BDNF and its precursor proBDNF in lymphocytes. In addition, earlier studies using commercial ELISA kits cannot distinguish mature BDNF from proBDNF. The measurement of mBDNF level could be a potential diagnostic marker with a cut-off point at 12.4 ng/ml. Upregulations of proBDNF and mBDNF in lymphocytes of MDD patients might be considered as novel pathological biomarkers for MDD.

JOURNAL OF PSYCHIATRIC RESEARCH (2021)

Article Clinical Neurology

BDNF and pro-BDNF in serum and exosomes in major depression: Evolution after antidepressant treatment

Thibaut Gelle et al.

Summary: This study found that BDNF levels were decreased and proBDNF levels were increased in both serum and exosomes in patients with Major Depression (MD). During antidepressant treatment, there was an inverse relationship in the levels of BDNF and proBDNF in serum and exosomes. However, these levels were not related to clinical improvement or depression scales.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2021)

Review Neurosciences

The Role of BDNF on Neural Plasticity in Depression

Yang Tao et al.

FRONTIERS IN CELLULAR NEUROSCIENCE (2020)

Review Clinical Neurology

Glial and neuronal markers in bipolar disorder: A meta -analysis testing S100B and NSE peripheral blood levels

Francesco Bartoli et al.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2020)

Review Neurosciences

PROneurotrophins and CONSequences

Rui O. Costa et al.

MOLECULAR NEUROBIOLOGY (2018)

Article Psychiatry

Decreased S100B serum levels after treatment in bipolar patients in a manic phase

Meng -Chang Tsai et al.

COMPREHENSIVE PSYCHIATRY (2017)

Article Clinical Neurology

S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression

Oliver Ambree et al.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2016)

Review Clinical Neurology

Serum S10013 in manic bipolar disorder patients: Systematic review and meta-analysis

Maria Ines da Rosa et al.

JOURNAL OF AFFECTIVE DISORDERS (2016)

Review Clinical Neurology

BDNF as a biomarker for successful treatment of mood disorders: A systematic & quantitative meta-analysis

Maryna Polyakova et al.

JOURNAL OF AFFECTIVE DISORDERS (2015)

Article Psychiatry

Risks of all-cause and suicide mortality in mental disorders: a meta-review

Edward Chesney et al.

WORLD PSYCHIATRY (2014)

Article Pharmacology & Pharmacy

Serum S100B Represents a New Biomarker for Mood Disorders

Matthias Schroeter et al.

CURRENT DRUG TARGETS (2013)

Article Medicine, Research & Experimental

Functions of S100 Proteins

R. Donato et al.

CURRENT MOLECULAR MEDICINE (2013)

Article Clinical Neurology

Upregulation of blood proBDNF and its receptors in major depression

Li Zhou et al.

JOURNAL OF AFFECTIVE DISORDERS (2013)

Review Obstetrics & Gynecology

Bipolar disorder differences between genders: special considerations for women

Patricia Vega et al.

WOMENS HEALTH (2011)

Article Psychiatry

Serum S100B and antioxidant enzymes in bipolar patients

Ana Cristina Andreazza et al.

JOURNAL OF PSYCHIATRIC RESEARCH (2007)